Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function

Omega-3 fatty acid prescription drugs, Vascepa (≥96% eicosapentaenoic acid [EPA] ethyl ester) and Lovaza (46.5% EPA and 37.5% docosahexaenoic acid ethyl ester) are known therapeutic regimens to treat hypertriglyceridemia. However, their impact on glucose homeostasis, progression to type 2 diabetes,...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Rijjal, Dana, Liu, Ying, Lai, Mi, Song, Youchen, Danaei, Zahra, Wu, Anne, Mohan, Haneesha, Wei, Li, Schopfer, Francisco J., Dai, Feihan F., Wheeler, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379293/
https://www.ncbi.nlm.nih.gov/pubmed/34458694
http://dx.doi.org/10.1016/j.isci.2021.102909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379293/
https://www.ncbi.nlm.nih.gov/pubmed/34458694
http://dx.doi.org/10.1016/j.isci.2021.102909

Ejemplares similares